INTRODUCTION
============

Recurrent cardiac ischemic events are equally attributed 497to culprit and non-culprit lesions (NCLs) in patients with acute coronary syndrome (ACS) ([@B1]). Among NCL patients, the lesions that are deemed to be responsible for these events are frequently characterized as mild ([@B2]); however, subsequent post-mortem studies on patients who died from major adverse cardiovascular events (MACEs) indicate that stenosis remains the strongest predictor of future events. Recent analyses may suggest an explanation for these discrepancies, with early studies failing to account for comorbidities, such as severe plaque progression, based on serial angiography and intravascular ultrasound (IVUS) ([@B3]).

As an important noninvasive imaging modality, coronary computed tomography angiography (CCTA) not only exhibits high diagnostic accuracy for significant stenosis but also accurately assesses coronary plaque morphology in combination with epicardial adipose tissue (EAT) volume ([@B4][@B5]). Beyond these functions, CCTA is currently applied to assess serial changes in plaques ([@B6]), with high-risk plaques and EAT volumes significantly associated with acute cardiovascular events ([@B7][@B8]). However, despite these extensive studies, the association between high-risk plaque features and EAT volume in cases of NCL plaque stenosis progression has not been evaluated, due in part to the lack of sufficient evidence regarding baseline features associated with progressive plaques. We intended to investigate the relationship between variables detected on CCTA and NCL plaque progression.

MATERIALS AND METHODS
=====================

Study Population
----------------

This study enrolled patients who had been successively treated by percutaneous coronary intervention (PCI) within 2 weeks after CCTA between August 1, 2011, and February 26, 2013, at the Chinese People\'s Liberation Army (PLA) General Hospital, Beijing, China. Upon enrollment, patients were scheduled for second CCTA examinations 12 months after the PCI and 3-year follow-up examinations after the second CCTA. During each CCTA examination, all relevant clinical and laboratory outcomes associated with cardiac risk factors were collected. Laboratory data including total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol, and triglyceride levels were obtained. Blood samples were collected within 1 week of CCTA, either before or after. We recorded all medical therapies prescribed after the first CCTA examination including aspirin, clopidogrel, statins, angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, and β-blockers.

The study was carried out in accordance with the code of Ethics of the World Medical Association (Declaration of Helsinki); the patients provided written informed consent prior to their inclusion in the study. The relevant protocols were approved by the Ethic Committees of the Chinese PLA General Hospital. Pharmaceutical and lifestyle changes were managed after the PCI according to AHA/ACC guidelines ([@B9]).

The exclusion criteria were as follows: 1) history of coronary artery bypass grafting surgery; 2) inadequate clinical and laboratory data; 3) poor or significantly reduced image quality based on the Likert scale at either baseline or follow-up CCTA ([@B10]); 4) severe calcification deemed non-evaluable lumen-diameter stenosis at either baseline or follow-up CCTA; 5) no NCLs after PCI; 6) failure to finish the PCI for the culprit lesion at our center; or 7) occurrence of MACEs between the first and second CCTA. Finally, a total of 103 patients were enrolled in this study ([Fig. 1](#F1){ref-type="fig"}) between August 2011 and February 2013.

Definitions
-----------

A NCL was defined as a *de novo* stenotic lesion that was not responsible for the ischemic symptoms or positive functional ischemic test outcomes ([@B11]). For the purpose of this study, previously untreated patients with stenosis \> 30% of coronary vessel diameter were defined as NCLs ([@B1]).

Hypertension was defined as having a history of blood pressure ≥ 140/90 mm Hg or using antihypertensive therapy. Dyslipidemia was defined as a TC level ≥ 220 mg/dL, LDL-C ≥ 140 mg/dL, or current treatment with lipid-lowering medication. Diabetes mellitus was defined as a fasting plasma glucose level ≥ 126 mg/dL or the use of antidiabetic therapy. Smoking was defined as a self-reported history of current smoking.

CCTA Imaging Protocols
----------------------

All examinations were performed on a dual-source CT scanner (Definition Flash; Siemens Healthcare, Forchheim, Germany); baseline and follow-up CCTA images were acquired using the same scanner for every patient. The data were acquired using a 2 x 64 x 0.6 mm detector collimation and gantry rotation of 280 ms. Different tube voltages were allocated to different patients based on body mass index (BMI). A tube voltage of 120 kVp was used when BMI ≥ 25 kg/m^2^, whereas those with a BMI \< 25 kg/m^2^ were examined using a tube voltage of 100 kVp. All patients received sublingual nitroglycerin (Nitroglycerin Aerosol; Jewim Pharmaceutical Co., Ltd., Taian, China) 3 minutes before their scans, and 60--80 mL contrast agent (based on body weight) was administered by intravenous injection ([@B12]).

Based on heart rates, different scanning protocols such as prospectively ECG--triggered high-pitch spiral double scans, step-on sequences, or retrospective spiral scans were allocated to different patients as appropriate. The CCTA image data were transferred to a workstation for multi-modality post-processing (MMWP 2011A, Siemens Healthcare).

CCTA Imaging Analysis
---------------------

Coronary computed tomography angiography images were analyzed by two experienced cardiologists who were blinded to the patients\' clinical information and outcomes, and all NCLs with a diameter ≥ 2 mm were examined. We excluded from this assessment segments that had been previously treated with a stent because mechanical interventions have been shown to affect plaque assessment. NCLs were examined in every patient: if multiple NCLs were present, the vessel with the largest decrease in diameter between two CCTA scans was used as the lesion to analyze for that patient. We categorized the severity of NCL stenosis into four grades by visual estimation: 1--49% for mild stenosis, 50--70% for moderate stenosis, and either \> 70% or \> 99% for severe stenosis or occlusion ([@B13]). We defined plaque progression in the NCLs as an increase in the stenosis grade at the follow-up CCTA examination ([@B14]). We first identified the site that exhibited the largest increase in stenosis, and from there we marked an area 5 mm proximal and 5 mm distal, for a total vessel length of 10 mm; we then analyzed high-risk plaque characteristics such as low attenuation plaque (LAP), positive remodeling (PR), and spotty calcification (SC). We defined the remodeling index as the cross-sectional area with maximal stenosis divided by the reference lesion\'s cross-section area, and we used a threshold of ≥ 1.1 to define PR ([@B15][@B16]). We defined LAP as \< 30 Hounsfield units (HU) within focal areas of interest in the plaque SC, which we defined as small calcified plaques with a diameter \< 3 mm ([@B5][@B17]). We measured plaque volume automatically based on attenuation (quantitative coronary analysis, syngo Circulation; Siemens Healthcare) and defined medium attenuation plaque as 30--150 HU. We defined calcified plaque as 350--1000 HU and defined lumen attenuation as 150--350 HU. We also analyzed each index lesion for total plaque volume.

We measured the EAT volume at baseline using volume analysis software (syngo Volume, Siemens Healthcare). From the bifurcation of the pulmonary artery to the diaphragm, we used all of the axial slices surrounding the heart for the analyses. Separately, we manually extracted 7 to 10 equidistant axial planes in parallel, and in each plane, the software automatically generated the region of interest by manually tracing with 8 to 12 control points. A threshold attenuation value of -195 to -45 HU units was then applied to isolate EAT. Finally, the software automatically calculated the EAT volume. Two experienced cardiologists performed all measurements who had been blinded to the patients\' clinical information.

Clinical Endpoints and Definitions
----------------------------------

The pre-specified primary endpoint was the occurrence of a MACE, including myocardial infarction (MI) and unstable angina pectoris, after the second CCTA examination required immediate revascularization. MI was diagnosed based on the typical chest pain, elevated myocardial enzyme levels, and typical changes on electrocardiogram. We defined unstable angina pectoris based on the Braunwald Unstable Angina Classification. Patients\' follow-up was conducted in 4-month intervals after the completion of the second CCTA examination. A telephone interviewer contacted each patient to inquire about MACEs.

Statistical Analyses
--------------------

The JMP software package (version 9.2; SAS Institute Inc., Cary, NC, USA) and SPSS 22.0 (IBM Corporation, Armonk, NY, USA) was used for all statistics analyses. Continuous variables were compared using Student\'s *t* tests or the Mann-Whitney U test as appropriate and are expressed as mean ± standard deviation; the categorical variables, compared with chi-square tests, are expressed as percentages. The significant variables (*p* \< 0.05) were included in the logistic regression analysis to identify factors that were independently associated with NCL plaque progression. The Kaplan-Meier estimation with a log-rank test was used to analyze the influence of NCL plaque progression detected by the second CCTA examination on event-free survival. All *p* values were two-sided, and a *p* \< 0.05 was considered statistically significant.

RESULTS
=======

Of the 103 patients, the median age was 60 years, 78.6% were male, and 20.39% had diabetes mellitus. NCL progression was observed in 34 (33%) of 103 patients ([Fig. 2](#F2){ref-type="fig"}). Among the patients who showed NCL progression, 12 progressed from mild to moderate stenosis, 8 from mild to severe stenosis, and 14 from moderate to severe stenosis. The average intra-reader variability for the two cardiologists was \< 3 mL, reflecting a high degree of reliability among the EAT volume measurements.

Baseline Demographics and Plaque Characteristics
------------------------------------------------

The baseline clinical characteristics of patients with and without NCL progression are presented in [Table 1](#T1){ref-type="table"}. Patients with NCL progression were more likely to exhibit a history of previous ST-elevation myocardial infarction (STEMI) (64.7% vs. 18.8 %, *p* \< 0.001), PR (50.0% vs. 11.6%, *p* \< 0.001), LAP (76.5% vs. 15.9%, *p* \< 0.001), and a high EAT volume (181 ± 53 vs. 128 ± 39, *p* \< 0.001). No other differences attained statistical significance.

The Lipid Profile and NCL Progression
-------------------------------------

Baseline TC levels were significantly higher in the progression NCL group compared with the non-progression group at both baseline and follow-up CCTA (3.91 ± 0.95 mmol/L vs. 3.54 ± 0.66 mmol/L, *p* = 0.039). LDL-C levels were significantly greater in patients with NCL progression compared with those with no progression at the time of follow-up (2.51 ± 0.88 mmol/L vs. 1.77 ± 0.51 mmol/L, *p* \< 0.001) ([Table 2](#T2){ref-type="table"}).

Assessing the Stents in the Culprit Lesions on the Follow-Up CCTA
-----------------------------------------------------------------

There was no significant in-stent restenosis of the treated culprit lesions in either group. Neointimal hyperplasia was observed in patients both with and without LDL progression at the time of follow-up (5.9% vs. 11.6%, *p* = 0.491).

Factors Association with NCL Progression Identified by Logistic Regression Analysis
-----------------------------------------------------------------------------------

Logistic analyses that incorporated history of STEMI, LAP, PR, EAT, and LDL-C as independent variables were used to identify factors associated with NCL progression. This analysis showed that a history of STEMI (odds ratio \[OR\] = 5.855, 95% confidence interval \[CI\] = 1.391--24.635, *p* = 0.016) or LAP (OR = 7.311, 95% CI = 1.242--43.028, *p* = 0.028), follow-up LDL levels (OR = 6.832, 95% CI = 2.103--22.200, *p* = 0.001), and history of EAT (OR = 1.015, 95% CI = 1.000--1.029, *p* = 0.044) were significant independent risk factors for NCL progression ([Table 3](#T3){ref-type="table"}); the area under the receiver operating characteristic curve was 0.794 for EAT volume alone (95% CI = 0.702--0.885, *p* \< 0.001) ([Fig. 3](#F3){ref-type="fig"}).

Clinical Outcomes
-----------------

During the 3-year post-CCTA follow-up period, MACEs occurred in 12 patients. In the progression group, unstable angina pectoris requiring immediate revascularization occurred in 6 patients and MI occurred in 2. In the non-progression group, unstable angina pectoris requiring immediate revascularization occurred in 1 patient and MI in an additional 3. In the Kaplan-Meier curve analysis, the progression group had an increased rate of NCLs related to MACEs, driven mainly by a higher revascularization rate and unstable or progressive angina symptoms during follow-up, as compared with the non-progression group (*p* = 0.006) ([Fig. 4](#F4){ref-type="fig"}).

DISCUSSION
==========

In the present analysis, we evaluated the associations between features detected on CCTA and NCL plaque progression, and we found that baseline LAP and EAT volume, follow-up LDL-C levels, and a history of STEMI were all independently associated with this progression. Our results suggest that CCTA-based assessment of imaging characteristics can predict NCL plaque progression independent of traditional risk factors, and NCL plaque progression was significantly associated with future MACEs. To our knowledge, this is the first description of the use of CCTA-based features to evaluate NCL plaque progression over time. This finding highlights the potential value of CCTA in identifying high-risk NCL and predicting disease outcomes.

LDL-C Levels and NCL Plaque Progression
---------------------------------------

Atherosclerotic progression in NCLs has been observed in patients who failed to achieve optimum LDL-C levels ([@B14]). Extensive studies highlight the pivotal role of hyperlipidemia in the pathogenesis of atherosclerosis ([@B18]). Lowering LDL-C levels using statins has been demonstrated to slow plaque progression due to absolute reductions in LDL-C levels; in our study, these levels were higher at follow-up than at baseline in patients with NCL plaque progression. Patients\' noncompliance and statin intolerance were the two main underliers of this finding. However, these observations were not investigated further.

In our study, NCL plaque progression was observed in patients with optimal follow-up LDL-C levels, largely consistent with prior studies. Despite substantial reductions in LDL-C levels, NCL progression continued in many patients, particularly those with preexisting rather than *de novo* NCLs, indicating that other factors likely contribute to NCL plaque progression ([@B19]).

History of STEMI and NCL Plaque Progression
-------------------------------------------

Our understanding of the association between NCL progression and STEMI is based primarily on two studies in which overall coronary instability was observed in acute myocardial infarction (AMI) ([@B20][@B21]). A direct comparison of NCL progression in patients with AMI and stable angina found that AMI was a significant risk factor for systematic progression involving multiple coronary artery plaques ([@B22]). Subsequent studies showed that AMI accelerated atherosclerosis in a mouse model, identifying that STEMI was an independent determinant of NCL progression ([@B11]). In the data presented here, we found that patients with a history of STEMI had a higher prevalence of NCL progression detected by CCTA, consistent with previous findings.

Characteristics Detected on CCTA and NCL Plaque Progression
-----------------------------------------------------------

Low-attenuation plaque, a high-risk plaque feature, was more frequently seen in patients with ACS ([@B4]). Non-obstructive plaque with vulnerable features identified by CCTA was associated with future ACS events ([@B23]). In addition, CCTA-verified high-risk plaque was an independent short-term and mid-term predictor of ACS ([@B24]). Among patients with visible plaques, those with calcification in the majority of these plaques exhibited a markedly lower risk of coronary heart disease compared with those with no calcification existed in the majority of plaques ([@B25]). Taken together, these publications strongly suggest that plaque consisting of low attenuation parts is associated with poor prognosis. However, a significant limitation of all these studies was that they predicted future cardiovascular events based on plaque features measured from a single time point. While the prognosis value of CCTA is important for routine patient care, the ability to evaluate NCL plaque progression before a cardiovascular event is essential because stenosis remains the strongest predictor of ACS. In the present study, we examined the likelihood of future MACEs in the context of NCL plaque progression initiated by high-risk plaque characteristics; high-risk plaques were observed in both NCLs and culprit lesions. The Providing Regional Observations to Study Predictors of Events in the Coronary Tree (PROSPECT) study demonstrated that clinical and angiographic information have poor predictive value in discriminating patients with untreated high-risk plaques and emphasized a need for more comprehensive plaque features detected by CCTA for more accurate risk stratification ([@B26]). In our study, we identified CCTA-verified LAP at baseline as an independent predictor of NCL stenosis progression. This process can be progressive, episodic with repeated silent plaque ruptures and healing, or characterized by worsening luminal stenosis with plaque rupture developing in lesions with large necrotic cores ([@B27]). LAP is a consistent high-risk plaque feature of lipid-rich plaques that contain large necrotic cores as assessed by virtual histology-IVUS ([@B28]). In a histogram analysis, lipid-rich plaques exhibited a higher percentage of areas with low CT attenuation values compared with plaques of predominantly fibrous components ([@B29]). The evidence presented here of increased LAP in patients with worsening NCLs was consistent with the results of the PROSPECT study, in which non-culprit plaque progression was induced by the cycle of necrotic core formation, rupture, and healing ([@B27]). However, our study extended beyond what can be inferred from PROSPECT because our patients underwent a second CCTA, which enabled comparisons between baseline and follow-up plaque stenosis. Such an analysis is consistent with a recent study that suggested that patients with high-risk plaque can benefit from serial CCTAs ([@B24]). Based on these analyses, it may be prudent to focus on NCL plaque progression in patients with CCTA-verified LAP at baseline.

Evidence of an association between EAT and NCL plaque progression is strongly supported by recent clinical investigations that identified a high EAT volume as a predictor of MACEs independent of conventional risk factors ([@B8]), and other studies strongly supported the role of EAT in atherosclerosis inception and progression ([@B30]). Despite these associations, little is known regarding the role of EAT in patients with NCL plaque stenosis progression after successful PCI. Our results demonstrated the association between EAT volume and NCL plaque progression in the patients who received serial CCTA examinations after successful PCI as determined by the CCTA exams, consistent with previous clinical investigations as well as observations in porcine modes of disease ([@B30]). Atherosclerosis was found to progress both proximally and distally relative to the site of EAT resection but not in segments that underlay EAT-resected areas. Beyond the link between epicardial fat volume and traditional risk factors, a number of trials have also shown a link between high epicardial fat volume and progression of coronary atherosclerosis, with no such correlation seen in patients with low epicardial fat volumes ([@B31]). Along these lines, EAT has been identified as an independent predictor of ACS and is thought to affect the development of atherosclerosis ([@B32]).

Recent studies showed that EAT volume is an independent predictor of in-stent restenosis ([@B33]), but due to the short interval between the two CCTAs in our study, we did not find significant restenosis for the culprit lesions; only a few culprit lesions with neointimal hyperplasia in the stent were observed.

CCTA and NCL Progression
------------------------

Recent updates to the clinical practice guideline for managing NCL in STEMI patients address a variety of advances in NCL therapy. However, an optimal method for evaluating NCLs is still needed due in part to insufficient data regarding the optimal timing of non-culprit vessel PCI. Previous studies have demonstrated the ability of CCTA to identify plaque progression over time ([@B14]), and multicenter trials such as the PROSPECT study have also emphasized the need for more comprehensive testing of NCL plaque morphology using noninvasive imaging for more accurate risk stratification. The data presented here strongly suggest that follow-up CCTA assessment of NCLs improved the non-invasive diagnosis of NCL progression and identified high-risk NCLs for further examination.

Potential Clinical Implications
-------------------------------

Identifying high-risk NCLs that are prone to plaque progression may be useful for predicting MACEs. Although IVUS remains the gold standard for assessing plaque progression, it is limited by its invasive nature and is not suitable for routine clinical testing. Furthermore, both clinical and angiographic characteristics have failed to identify high-risk NCLs as predicting future adverse events. Identifying a non-invasive method for predicting disease outcomes may present a more attractive alternative to comprehensive three-vessel imaging assessment, which could help identify high-risk lesions and improve risk assessment and disease management in at-risk patients.

Study Limitations
-----------------

The small, single-center nature of this study is its most significant limitation, but the potential for selection bias is also an important consideration given the small number of patients who underwent serial CCTA examinations. Large-scale multicenter prospective studies are therefore necessary to confirm the results of this study to establish better models of NCL risk stratification. Secondly, compared with the PROSPECT trial, more definitive plaque information such as presence of a thin-cap fibroatheroma, plaque burden, or minimal lumen area could not be analyzed by CCTA, although correlations between high-risk plaque features detected on CCTA and vulnerable plaques detected by IVUS and optical coherence tomography have been reported; the referral bias made it difficult to perform adequate comparisons with the PROSPECT trial. Third, most MACE outcomes were largely by driven by revascularization, which is considered a "soft endpoint." We were unable to obtain follow-up angiography data for all patients after the second CCTA examination, and thus other factors that affect disease outcomes, such as treated culprit lesions, could not be eliminated. Finally, the methodology of quantitative plaque volume analysis by Siemens software was not well-validated against IVUS or other high-resolution imaging modalities, but we did not assess plaque progression with this software volume; the software did provide some supplementary information about plaque volume.

Conclusion
----------

This study showed that serial CCTA evaluation allows for assessing interval changes in NCL and identifying clear associations between NCL plaque progression and baseline features detected on CCTA. This CCTA study provides new data that reveal clear associations among baseline LAP, EAT volume, and NCL plaque progression, even after adjustment for conventional risk factors. Additional studies will be necessary to establish a new model of NCL risk stratification.

![Flow chart illustrating study population.\
CABG = coronary artery bypass grafting surgery, CAD = coronary artery disease, CCTA = coronary computed tomography angiography, MACE = major adverse cardiovascular event, PCI = percutaneous coronary intervention](kjr-18-487-g001){#F1}

![Assessment of plaque progression by CCTA.\
**A, C.** NCL in baseline MPR cross-section and luminal stenosis measurements. **B, D.** Same lesion at follow-up CCTA. CCTA = coronary computed tomography angiography, MPR = multiplanar reconstruction, NCL = non-culprit lesion](kjr-18-487-g002){#F2}

![Area under receiver operating characteristic curve was 0.794 for EAT volume alone (95% CI = 0.702--0.885, *p* \< 0.0001).\
CI = confidence interval, EAT = epicardial adipose tissue](kjr-18-487-g003){#F3}

![Kaplan-Meier curves for MACE-free survivor during 3-year post-CCTA follow-up period.\
CCTA = coronary computed tomography angiography, MACE = major adverse cardiovascular event](kjr-18-487-g004){#F4}

###### Baseline Demographics and Plaque Characteristics

![](kjr-18-487-i001)

                                      Progression (n = 34)   Non-Progression (n = 69)   *P*
  ----------------------------------- ---------------------- -------------------------- --------------
  Age, years old                      60.7 ± 8.4             63.7 ± 12.7                0.146
  BMI, kg/m^2^                        26.08 ± 3.28           25.74 ± 3.17               0.627
  Male sex, n (%)                     28 (82.4)              53 (76.8)                  0.615
  Hypertension, n (%)                 8 (23.5)               22 (31.9)                  0.491
  Dyslipidemia, n (%)                 9 (26.5)               19 (27.5)                  \> 0.99
  Diabetes mellitus, n (%)            4 (11.8)               17 (24.6)                  0.193
  Family history of CAD, n (%)        6 (17.6)               8 (11.6)                   0.542
  Smoking, n (%)                      6 (17.6)               20 (29.0)                  0.239
  Medications, n (%)                                                                    
   Aspirin                            34 (100)               67 (97.1)                  \> 0.99
   Clopidogrel                        29 (85.3)              61 (88.4)                  0.754
   statin                             27 (79.4)              50 (72.5)                  0.482
   Trimetazidine                      26 (76.5)              47 (68.1)                  0.491
   ACE-I or ARBs                      5 (14.7)               16 (23.2)                  0.438
   Beta-blocker                       23 (67.6)              47 (68.1)                  \> 0.99
   History of STEMI                   22 (64.7)              13 (18.8)                  \< 0.001^\*^
  Target coronary artery, n (%)                                                         0.135
   LM                                 4 (11.8)               1 (1.4)                    
   LAD                                12 (35.3)              30 (43.5)                  
   LCX                                11 (32.4)              21 (30.4)                  
   RCA                                7 (20.6)               17 (24.6)                  
   PR                                 17 (50.0)              8 (11.6)                   \< 0.001^\*^
   LAP                                26 (76.5)              11 (15.9)                  \< 0.001^\*^
   SC                                 12 (35.3)              28 (40.6)                  0.671
  Luminal stenosis                                                                      
   30--50%                            16 (47.1)              52 (75.4)                  
   50--70%                            18 (52.9)              17 (24.6)                  \> 0.99
   EAT (mL)                           181 ± 53               128 ± 39                   \< 0.001^\*^
   Plaque volume, mm^3^               27.10 ± 7.73           26.64 ± 12.40              0.14
   Interval between two CCTAs, days   327 ± 12               332 ± 15                   0.09

Data are expressed as mean ± SD, percentages as appropriate. ^\*^*p* \< 0.05. ACEI = angiotensin-converting enzyme inhibitors, ARBs = angiotensin II receptor blockers, BMI = body mass index, CAD = coronary artery disease, CCTA = coronary computed tomography angiography, EAT = epicardial adipose tissue, LAD = left anterior descending, LAP = low-attenuation plaque, LCX = left circumflex artery, LM = left main, NCL = non-culprit lesion, PR = positive remodeling, RCA = right coronary artery, SC = spotty calcification, STEMI = ST-elevation myocardial infarction

###### Lipid Profile and Progression of Non-Culprit Lesion
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                    Progression (n = 34)   Non-Progression (n = 69)   *P*
  ----------------- ---------------------- -------------------------- --------------
  TC (mmol/L)                                                         
   Baseline CCTA    3.91 ± 0.95            3.54 ± 0.66                0.039^\*^
   Follow-up CCTA   3.77 ± 0.71            3.64 ± 0.89                0.467
  TG (mmol/L)                                                         
   Baseline CCTA    1.37 ± 0.74            1.42 ± 0.83                0.747
   Follow-up CCTA   1.21 ± 0.56            1.34 ± 0.75                0.340
  LDL-C (mmol/L)                                                      
   Baseline CCTA    2.27 ± 0.74            2.13 ± 0.73                0.356
   Follow-up CCTA   2.51 ± 0.88            1.77 ± 0.51                \< 0.001^\*^
  HDL-C (mmol/L)                                                      
   Baseline CCTA    1.05 ± 0.35            1.12 ± 0.39                0.354
   Follow-up CCTA   1.05 ± 0.35            1.12 ± 0.35                0.266

Data are expressed as mean ± SD. ^\*^*p* \< 0.05. CCTA = coronary computed tomography angiography, HDL-C = high-density lipoprotein cholesterol, LDL-C = low-density lipoprotein cholesterol, TC = total cholesterol, TG = triglyceride

###### Factors Associated with Non-Culprit Lesion Progression Identified by Logistic Regression Analysis
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  ---------------------------------------------------------------------------------------
          Univariate               Multivariate^\*^                           
  ------- ------------------------ ------------------ ----------------------- -----------
  LDL2    5.191 (2.382--11.313)    \< 0.001^\*^       6.832 (2.103--22.200)   0.001^\*^

  LAP     17.136 (6.170--47.592)   \< 0.001^\*^       7.311 (1.242--43.028)   0.028^\*^

  STEMI   7.897 (3.126--19.951)    \< 0.001^\*^       5.855 (1.391--24.635)   0.016^\*^

  PR      7.625 (2.812--20.676)    \< 0.001^\*^       1.718\                  0.578
                                                      --                      

  EAT     1.027 (1.014--1.039)     \< 0.001^\*^       1.015 (1.000--1.029)    0.044^\*^
  ---------------------------------------------------------------------------------------

CI and adjusted OR was obtained after controlling for age, sex, BMI, hypertension, hyperlipidemia, diabetes mellitus, family history of CAD, history of medications by logistic regression analysis. ^\*^*p* \< 0.05. BMI = body mass index, CI = confidence interval, EAT = epicardial adipose tissue, LAP = low attenuation plaque, LDL2 = follow-up low-density lipoprotein cholesterol, OR = odds ratio, PR = positive remodeling, STEMI = ST-elevation myocardial infarction
